bluebird bio (NASDAQ: BLUE) reported Q4 EPS of $0.38, $0.76 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $884.67 thousand.

LOVO-CEL

• BLA submission anticipated following response from FDA on analytical comparability data in the coming weeks.
• The Company continues to anticipate commercial launch in early 2024, if approved.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.